Biodesix announces preliminary fourth quarter and full-year 2021 revenue (unaudited)

Boulder, colo.--(business wire)--biodesix, inc. (nasdaq: bdsx) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the company expects to report fourth quarter and record full-year 2021 preliminary unaudited total revenue of $7.2 million and $54.5 million, respectively. the strength in the full-year 2021 total revenue of $54.5 million compared to $45.6 million in 2020 was a result of growth in the company's core lung diagnostic testing and first
BDSX Ratings Summary
BDSX Quant Ranking